Genelabs, Incorporated

The University of North Carolina at Chapel Hill

Genelabs Technologies, Inc.

Su-Ying Liu

Kou M Hwang

You M Qi

Jen Chen

William Choy

Yung-Chi Cheng

Kuo-Hsiung Lee

Thomas C Lee

J Phillip Bowen

Zhe Oing Wang

Masami Mori

Yao H Kuo

Dora M Schnur

A method for inhibiting cell infection by an enveloped virus, by administering to an infection site, a therapeutically effective amount of a calix(n)arene compound derivatized, at its ring positions meta to the bridge attachements to the ring, with polar substitutent having a terminal carboxylate, phosphate, or sulfonate groups, including esters and amides which are cleavable in vivo. The compound may be administered orally, or topically, e.g., for treatment of herpes virus.

Treatment of infection by enveloped virus with calix(N)arene compounds

A method of inhibiting thrombus formation in a mammalian subject. The method involves administering to the subject a therapeutically effective dose of a calix(n)arene compound derivatized, at its ring positions meta to the bridge attachments to the ring, with polar substituents having terminal sulfonate groups, including esters and amides which are cleavable in vivo.

Antithrombotic treatment with calix(n)arene compounds

A method for inhibiting cell infection by an enveloped virus, by administering to an infection site, a therapeutically effective amount of a macrocyclic compound composed of aryl ring subunits connected one to another by ring-attached bridge linkages, and containing sulfonic acid-derived substituents carried on non-bridge atoms of the subunits.

Method of treating viral infections with aryl macrocyclic compounds

A compound and method for inhibiting cell infection by an enveloped virus. The compound is a macrocyclic chromotropic acid derivative which can be substituted at a variety of naphthalene ring and bridge positions. The compound may be administered parenterally, orally, or topically for treating infection by enveloped viruses.

Macrocyclic anti-viral compound and method

A method of inhibiting cell infection by herpes simplex virus-1 or -2. The method includes contacting the virus with a macrocyclic chromotropic acid compound, in an amount effective to inhibit cell infectivity of the virus.

Method of treating herpes simplex virus infection

Compounds that are analogs of etoposide and exhibit antitumor activity are disclosed. The compounds of the present invention have the following formula: ##STR1## where: R.sub.1 is .beta.-OCH.sub.2 CH.sub.2 NH.sub.2 .beta.-NHCH(CH.sub.3)CH.sub.2 OH, .beta.-NHCH.sub.2 CH(CH.sub.3)OH, .beta.-Cl, .beta.-Br, .beta.-OH, .alpha.-OH, .beta.-NH, .alpha.-NH.sub.2, .beta.-NHCH.sub.2 CH.sub.2 OH, .alpha.-NHCH.sub.2 CH.sub.2 OH, .beta.-NHCH.sub.2 CH.sub.2 CH.sub.3, .beta.-NHCH.sub.2 CH.sub.2 OCH.sub.3, .beta.-NHCH.sub.2 CH.dbd.CH.sub.2, .beta.-NHCH.sub.2 CH(OH)CH.sub.3, .beta.-NHCH.sub.2 CH.sub.2 CH.sub.2 OH, .beta.-OCH.sub.2 CH.sub.2 OH, ##STR2## R.sub.2 is H, or Br; R.sub.1 is H, or Br;

Growing community of inventors

Belmont, CA, United States of America

Su-Ying Liu